{
  "id": "29bb6759bceee24d",
  "title": "MRM Health NV : MRM Health erh\u00e4lt FDA - Zulassung f\u00fcr Start der Phase - 2b - Studie mit MH002 bei leichter bis mittelschwerer Colitis ulcerosa",
  "description": "20260109T070000Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2026-01/67393397-mrm-health-nv-mrm-health-erhaelt-fda-zulassung-fuer-start-der-phase-2b-studie-mit-mh002-bei-leichter-bis-mittelschwerer-colitis-ulcerosa-004.htm",
  "published_at": "20260109T070000Z",
  "fetched_at": "2026-01-10T00:22:56.872596+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2026-01/67393397-mrm-health-nv-mrm-health-erhaelt-fda-zulassung-fuer-start-der-phase-2b-studie-mit-mh002-bei-leichter-bis-mittelschwerer-colitis-ulcerosa-004.htm",
    "url_mobile": "",
    "title": "MRM Health NV : MRM Health erh\u00e4lt FDA - Zulassung f\u00fcr Start der Phase - 2b - Studie mit MH002 bei leichter bis mittelschwerer Colitis ulcerosa",
    "seendate": "20260109T070000Z",
    "socialimage": "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20260108069659r1&sid=gefi2&distro=ftp",
    "domain": "finanznachrichten.de",
    "language": "German",
    "sourcecountry": "Germany"
  }
}